Bristol-Myers Squibb reported better-than-expected results for the first quarter of 2019 on the performance of its blood thinner drug, Eliquis. First-quarter 2019 earnings of $1.10 per share beat analyst estimates by one cent and surpassed the year-ago quarter’s earnings of $0.94.
Total revenue of $5.92 billion beat expectations of $5.80 billion and increased 14% from $5.2 billion in the year-ago period. Continued strong sales of Opdivo and Eliquis contributed to the top line in the reported quarter.